RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9500
-0.0492 (-4.92%)
Feb 19, 2026, 10:19 AM EST - Market open
RenovoRx Employees
RenovoRx had 10 employees as of December 31, 2024. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change
2
Growth
25.00%
Revenue / Employee
$92,800
Profits / Employee
-$1,110,500
Market Cap
34.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| NeuroSense Therapeutics | 17 |
| Outlook Therapeutics | 17 |
| Atossa Therapeutics | 15 |
RNXT News
- 9 days ago - RenovoRx Establishes RenovoCath® Medical Advisory Board - GlobeNewsWire
- 14 days ago - RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer - GlobeNewsWire
- 15 days ago - RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting - GlobeNewsWire
- 22 days ago - RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting - GlobeNewsWire
- 4 weeks ago - RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - GlobeNewsWire
- 5 weeks ago - RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 - GlobeNewsWire
- 6 weeks ago - RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - GlobeNewsWire
- 2 months ago - RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - GlobeNewsWire